Bevacizumab Does Not Improve Survival in Newly-Diagnosed Glioblastoma
Among patients with newly-diagnosed glioblastoma, adding bevacizumab to standard first-line chemoradiotherapy does not improve survival, found data presented at ASCO 2013.
Among patients with newly-diagnosed glioblastoma, adding bevacizumab to standard first-line chemoradiotherapy does not improve survival, found data presented at ASCO 2013.
In peritumoral cerebral edema, corticorelin acetate improves steroid-induced myopathy.
Understanding the etiology of seizures in patients with cancer can be complex, and clinicians must carefully consider many factors to properly manage them.
For pediatric patients with stage 4 neuroblastoma, surgery of the primary tumor site has no impact on outcomes.
For patients receiving radiotherapy for glioblastoma (GBM), use of clinical target volume (CTV) margins as small as 5 mm does not lead to an increase in marginal failures.
FSRT is safe and effective for cranial neuropathies among patients with skull base meningiomas, but the risk of local failure is high among patients with a history of previous brain radiotherapy.
Patients with high-grade glioma receiving AEDsvalproic acid or levetiracetam did not experience drug-related cognitive declines.
Canadian researchers have identified a novel anticancer steroid biosynthesis inhibitor that might prove useful against pediatric low grade gliomas.
Magnetic resonance imaging (MRI) is “highly” predictive of OS rates after bevacizumab-based VEGF blockade chemotherapy for glioblastoma multiforme.
Insurance coverage affects in-hospital mortality for brain tumor patients undergoing craniotomy